Literature DB >> 30241732

Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease.

Hayato Tada1, Masa-Aki Kawashiri2, Akihiro Nomura3, Ryota Teramoto2, Kazuyoshi Hosomichi4, Atsushi Nohara2, Akihiro Inazu5, Hiroshi Mabuchi2, Atsushi Tajima4, Masakazu Yamagishi2.   

Abstract

BACKGROUND: The genetic background of severe familial hypercholesterolemia (FH) has yet to be determined.
OBJECTIVE: We tested if genetic variants associated with low-density lipoprotein (LDL)-altering autosomal recessive diseases influenced LDL cholesterol levels and the odds for coronary artery disease in patients with high LDL cholesterol.
METHODS: We recruited 500 individuals with elevated LDL cholesterol levels (≥180 mg/dL or ≥140 mg/dL for subjects <15 years). We sequenced the exons of 3 FH genes (LDLR, apolipoprotein B, and proprotein convertase subtilisin/kexin type 9) and 4 LDL-altering accessory genes (ABCG5, ABCG8, APOE, and LDL receptor adaptor protein 1). In addition, 4 single nucleotide polymorphisms associated with polygenic FH in East Asian subjects were genotyped. Oligogenic FH patients were defined as those who harbored damaging variants of both conventional FH genes and LDL-altering accessory genes.
RESULTS: We identified damaging variants of conventional FH genes in 248 participants (50%). We also detected damaging variants in accessory genes in 57 patients (11%) and identified oligogenic FH in 27 of these patients (5%). Polygenic score in the subjects without any FH mutations was significantly higher than those in any other groups. Compared with monogenic FH, oligogenic FH exhibited significantly higher LDL cholesterol (265 mg/dL, 95% confidence interval [CI] 216-312, and 210 mg/dL, 95% CI 189-243; P = .04). Oligogenic FH exhibited higher odds for coronary artery disease when compared with monogenic FH, although it did not reach statistical significance (odds ratio 1.41, 95% CI 0.68-2.21, P = .24).
CONCLUSIONS: Among patients with elevated LDL cholesterol, those with oligogenic FH had higher LDL cholesterol than monogenic FH.
Copyright © 2018 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Familial hypercholesterolemia; Genetics; Low-density lipoprotein cholesterol; PCSK9

Mesh:

Substances:

Year:  2018        PMID: 30241732     DOI: 10.1016/j.jacl.2018.08.006

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  18 in total

1.  A reassessment of the Japanese clinical diagnostic criteria of familial hypercholesterolemia in a hospital-based cohort using comprehensive genetic analysis.

Authors:  Hayato Tada; Hirofumi Okada; Akihiro Nomura; Atsushi Nohara; Soichiro Usui; Kenji Sakata; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  Pract Lab Med       Date:  2020-10-19

Review 2.  Personalized medicine for cardiovascular diseases.

Authors:  Hayato Tada; Noboru Fujino; Akihiro Nomura; Chiaki Nakanishi; Kenshi Hayashi; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  J Hum Genet       Date:  2020-08-08       Impact factor: 3.172

3.  Genetic Analysis of Japanese Children Clinically Diagnosed with Familial Hypercholesterolemia.

Authors:  Keiko Nagahara; Tsuyoshi Nishibukuro; Yasuko Ogiwara; Kento Ikegawa; Hayato Tada; Masakazu Yamagishi; Masa-Aki Kawashiri; Ayako Ochi; Junya Toyoda; Yuya Nakano; Masanori Adachi; Katsumi Mizuno; Yukihiro Hasegawa; Kazushige Dobashi
Journal:  J Atheroscler Thromb       Date:  2021-05-20       Impact factor: 4.394

4.  Effects of Different Types of Pathogenic Variants on Phenotypes of Familial Hypercholesterolemia.

Authors:  Hayato Tada; Nobuko Kojima; Kan Yamagami; Akihiro Nomura; Atsushi Nohara; Soichiro Usui; Kenji Sakata; Noboru Fujino; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  Front Genet       Date:  2022-04-11       Impact factor: 4.772

Review 5.  Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology.

Authors:  Hayato Tada; Soichiro Usui; Kenji Sakata; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  J Atheroscler Thromb       Date:  2020-04-30       Impact factor: 4.928

6.  Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat.

Authors:  Yuanyuan Meng; Yong Liu; Ningning Fang; Yongmin Guo
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.889

Review 7.  Homozygous Familial Hypercholesterolemia.

Authors:  Atsushi Nohara; Hayato Tada; Masatsune Ogura; Sachiko Okazaki; Koh Ono; Hitoshi Shimano; Hiroyuki Daida; Kazushige Dobashi; Toshio Hayashi; Mika Hori; Kota Matsuki; Tetsuo Minamino; Shinji Yokoyama; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-04-18       Impact factor: 4.928

8.  A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene.

Authors:  Hayato Tada; Hirofumi Okada; Akihiro Nomura; Atsushi Nohara; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  Intern Med       Date:  2020-03-15       Impact factor: 1.271

9.  Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene.

Authors:  Hayato Tada; Hirofumi Okada; Akihiro Nomura; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  Lipids Health Dis       Date:  2020-01-04       Impact factor: 3.876

10.  Compound heterozygous variants in the ABCG8 gene in a Japanese girl with sitosterolemia.

Authors:  Nobuhiro Hashimoto; Sumito Dateki; Eri Suzuki; Takatoshi Tsuchihashi; Aiko Isobe; Sari Banno; Tomoka Kageyama; Naonori Maeda; Naomi Hatabu; Rieko Sato; Masashi Miharu; Hisayo Fujita; Osamu Komiyama; Hitomi Shimizu; Tomonobu Hasegawa; Kazuki Yamazawa
Journal:  Hum Genome Var       Date:  2020-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.